168 related articles for article (PubMed ID: 36030395)
1. A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Lin Y; Park Y; Khanal A; Campbell-Lee S; Liu L; Chen Z; Patel P; Vidanovic V; Sweiss K; Irene G; Peace D; Rondelli D; Mahmud N
Eur J Haematol; 2022 Dec; 109(6):711-718. PubMed ID: 36030395
[TBL] [Abstract][Full Text] [Related]
2. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
4. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
5. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
[TBL] [Abstract][Full Text] [Related]
6. Impact of mobilization regimen on multiday collection of peripheral blood CD34+ cells by large volume leukapheresis.
Siddiqui I; Shmookler A; Biller E; Hardy T; Hartage R; Losos M; Chen J
Transfusion; 2022 Apr; 62(4):857-862. PubMed ID: 35211978
[TBL] [Abstract][Full Text] [Related]
7. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR
Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
10. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
12. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
Kurnikova E; Trakhtman P; Balashov D; Garloeva J; Kumukova I; Khismatullina R; Pershin D; Shelikhova L; Novichkova G; Maschan A
Vox Sang; 2022 Jun; 117(6):853-861. PubMed ID: 35332550
[TBL] [Abstract][Full Text] [Related]
14. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
16. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34
Imoto N; Kondo Y; Uchida K; Kurahashi S
Intern Med; 2024 Jan; 63(2):189-195. PubMed ID: 37225486
[TBL] [Abstract][Full Text] [Related]
20. An innovation in stem cell harvesting: Heparin use.
Gul HG; Erkurt MA; Sarici A; Kuku I; Kaya E; Berber I; Merter M; Bicim S; Ozgul M
Transfus Apher Sci; 2021 Oct; 60(5):103240. PubMed ID: 34404617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
